ScholarIQanswers from OpenAlex & ORCID
Camillo Porta
ResearcherPublications, citations & collaboration network
Camillo Porta is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Camillo Porta have?
ScholarIQindexed works
Camillo Porta has 987 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Camillo Porta have?
ScholarIQcitation count
Camillo Porta has 58,290 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Camillo Porta?
ScholarIQh-index
Camillo Porta has an h-index of 80 in OpenAlex.
What is the i10-index of Camillo Porta?
ScholarIQi10-index
Camillo Porta has an i10-index of 434 in OpenAlex.
What is the ORCID of Camillo Porta?
ScholarIQorcid
The ORCID for Camillo Porta is on the source record.
What is the OpenAlex record for Camillo Porta?
ScholarIQopenalex
The OpenAlex for Camillo Porta is on the source record.
What are the most-cited papers on Camillo Porta?
ScholarIQmost cited works
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Nizar M. Tannir, Ray McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Victoria Neiman, Christian Kollmannsberger, Pamela Salman, Howard Gurney, Robert D. Hawkins, Alain Ravaud, Marc‐Oliver Grimm, Sergio Bracarda, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Allen C. Chen, Sabeen Mekan, M. Brent McHenry, Megan Wind‐Rotolo, Justin Doan, Padmanee Sharma, Hans J. Hammers, Bernard Escudier
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María José Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung‐Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frédéric Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Toni K. Choueiri, Thomas Powles, Mauricio Burotto, Bernard Escudier, María T. Bourlon, Bogdan Żurawski, Víctor Manuel Oyervides-Juárez, James J. Hsieh, Umberto Basso, Amishi Y. Shah, Cristina Suárez, Alketa Hamzaj, Jeffrey C. Goh, Carlos H. Barrios, Martin Eduardo Richardet, Camillo Porta, Rubén Dario Kowalyszyn, Juan P. Feregrino, Jakub Żołnierek, David Pook, Elizabeth R. Kessler, Yoshihiko Tomita, Ryuichi Mizuno, Jens Bedke, Joshua Zhang, Matthew Maurer, Burçin Şimşek, Flavia Ejzykowicz, Gisela Schwab, Andrea B. Apolo, Robert J. Motzer
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Martin Gore, Cezary Szczylik, Camillo Porta, Sergio Bracarda, Georg A. Bjarnason, Stéphane Oudard, Subramanian Hariharan, Se‐Hoon Lee, John B.A.G. Haanen, Daniel Castellano, Eduard Vrdoljak, Patrick Schöffski, Paul N. Mainwaring, Alejandra Nieto, Jinyu Yuan, Ronald M. Bukowski
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T. Powles, Laurence Albigès, Axel Bex, Éva Compérat, Viktor Grünwald, Ravindran Kanesvaran, H. Kitamura, R. McKay, Camillo Porta, G. Procopio, Manuela Schmidinger, Cristina Suárez, Jeremy Yuen‐Chun Teoh, Guillermo de Velasco, Matthew R. Young, Silke Gillessen